{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:35:00Z","timestamp":1762004100939},"reference-count":10,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10,1]]},"DOI":"10.1210\/jc.2008-0579","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T17:39:06Z","timestamp":1223487546000},"page":"3730-3732","source":"Crossref","is-referenced-by-count":51,"title":["Adjuvant Mitotane for Adrenocortical Cancer\u2014A Recurring Controversy"],"prefix":"10.1210","volume":"93","author":[{"given":"Hui","family":"Huang","sequence":"first","affiliation":[{"name":"Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tito","family":"Fojo","sequence":"additional","affiliation":[{"name":"Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071614095518800_R1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0022-4731(73)90033-2","article-title":"Complexing of DDT and o,p\u2032DDD with adrenal cytochrome P-450 hydroxylating systems.","volume":"4","author":"Young","year":"1973","journal-title":"J Steroid Biochem"},{"key":"2020071614095518800_R2","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/1097-0142(197811)42:5<2177::AID-CNCR2820420514>3.0.CO;2-X","article-title":"o,p\u2032-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.","volume":"42","author":"Hogan","year":"1978","journal-title":"Cancer"},{"key":"2020071614095518800_R3","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma.","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071614095518800_R4","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMc076267","article-title":"Adjuvant mitotane in adrenocortical carcinoma","volume":"357","author":"Bertherat","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071614095518800_R5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-53-4-672","article-title":"Chemotherapy of adrenocortical cancer with o,p\u2032 DDD.","volume":"53","author":"Bergenstal","year":"1960","journal-title":"Ann Intern Med"},{"key":"2020071614095518800_R6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0002-9343(66)90219-1","article-title":"Adrenal cortical carcinoma. Clinical features of 138 patients.","volume":"41","author":"Hutter Jr","year":"1966","journal-title":"Am J Med"},{"key":"2020071614095518800_R7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/jama.1973.03220100011003","article-title":"Mitotane use in inoperable adrenal cortical carcinoma.","volume":"223","author":"Lubitz","year":"1973","journal-title":"JAMA"},{"key":"2020071614095518800_R8","first-page":"2234","article-title":"Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.","volume":"85","author":"Terzolo","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614095518800_R9","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","article-title":"Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2032DDD) levels on the treatment of patients with adrenocortical carcinoma.","volume":"92","author":"Baudin","year":"2001","journal-title":"Cancer"},{"key":"2020071614095518800_R10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0277-5379(84)90033-6","article-title":"The treatment of adrenocortical carcinoma with o,p\u2032-DDD: prognostic implications of serum level monitoring.","volume":"20","author":"van Slooten","year":"1984","journal-title":"Eur J Cancer Clin Oncol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/10\/3730\/9052893\/jcem3730.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/10\/3730\/9052893\/jcem3730.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:32:34Z","timestamp":1594949554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/10\/3730\/2627283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,1]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-0579","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,1]]}}}